Skip to main content

Bridget Doherty, MPH, MS

Quality Outlook
03/05/2025
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research...
03/05/2025
Journal of Clinical Pathways